Author: Vitaliy Dadalyan

Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial

Pfizer's German development partner BioNTech on Thursday joined other leading COVID-19 vaccine developers in ruling out participation in British plans to test experimental inoculations by deliberately infecting trial volunteers. "BioNTech's vaccine candidate is not part of this study," a spokeswoman said. Britain is planning to host so-called "challenge trials", the Financial Times cited people involved in the project as saying....

The Coming 5G Boom Is Not Fully Priced in These 2 Stocks

5G, first introduced two years ago, is expanding past its initial phases and has reached the edge of a great boom. There are 105 5G networks worldwide, and device manufacturers have released over 160 5G smartphones, tablets, and other products onto the commercial market – and there are over 230 million 5G subscribers worldwide. The new tech is here, and it’s ready to expand.That expansion will bring a series of benefits to wireless users. The higher speeds on the networks have gotten the most attention, but 5G will also over 10 times higher data transfer rates, one-tenth the network latency, and far higher connection density capabilities. That last may turn out to be the key to 5G’s long-term success, as related technologies like IoT, autonomous cars, and smart homes multiply the connected devices in our lives.The expansion and benefits of 5G have attracted attention from some of Wall Street’s high-rated analysts;...